Brii Biosciences Limited Stock
Stocks
2137
KYG1645A1094
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Hong Kong S.E.
04:08:08 2026-08-21 EDT
|
5-day change | 1st Jan Change | ||
| 1.015 HKD | +3.57% |
|
+3.05% | -28.01% |
| Market Cap | 628M 733M 93.45M 80.05M 74.9M 68.56M 129M 8.94B 130M 885M 345M 4.49B 351M 343M 14.86B | P/E 2024 |
-1.32x | P/E 2025 | -4.11x |
|---|---|---|---|---|---|
| Enterprise Value | -1.3B -1.52B -194M -166M -155M -142M -267M -18.54B -270M -1.83B -715M -9.31B -727M -712M -30.8B | EV / Sales 2024 |
-32.4x | EV / Sales 2025 | -28.6x |
| Free-Float |
93.34% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Brii Biosciences Limited
| 1 day | +3.57% | ||
| 1 week | +3.05% | ||
| Current month | +7.98% | ||
| 1 month | +0.50% | ||
| 3 months | -15.42% | ||
| 6 months | -34.94% | ||
| Current year | -28.01% |
| 1 week | 0.94 |  | 1.14 |
| 1 month | 0.9 | | 1.14 |
| Current year | 0.9 | | 1.7 |
| 1 year | 0.9 | | 2.34 |
| 3 years | 0.8 | | 3.5 |
| 5 years | 0.8 | | 52.6 |
| 10 years | 0.8 | | 52.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Hong
CEO | Chief Executive Officer | 62 | 2018-02-22 |
An Kang Li
DFI | Director of Finance/CFO | 48 | 2020-08-31 |
Brian Johns
CTO | Chief Tech/Sci/R&D Officer | - | 2024-01-02 |
| Director | Title | Age | Since |
|---|---|---|---|
Zhi Hong
CHM | Chairman | 62 | 2021-03-23 |
Martin Murphy
BRD | Director/Board Member | 83 | 2021-06-21 |
Hui Tang
BRD | Director/Board Member | 66 | 2021-06-21 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.57% | +3.05% | -50.00% | -65.71% | 93.45M | |
| -3.00% | +2.27% | +77.60% | +109.33% | 72.12B | |
| +1.90% | +23.53% | +56.60% | +97.76% | 65.85B | |
| +5.12% | +25.22% | +5.24% | -0.82% | 29.28B | |
| +0.55% | +1.64% | -5.15% | +471.68% | 27.47B | |
| +2.74% | +12.98% | +62.84% | +28.14% | 26.7B | |
| +0.47% | +6.12% | +36.66% | -13.79% | 20.06B | |
| +1.82% | -6.67% | +247.46% | +393.10% | 18.22B | |
| +0.94% | +3.36% | +18.55% | +532.94% | 16.4B | |
| +0.73% | +5.54% | +39.71% | +153.07% | 13.4B | |
| Average | +1.48% | +7.83% | +48.95% | +170.57% | 28.96B | |
| Weighted average by Cap. | +0.74% | +9.48% | +59.01% | +157.73% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 49.94M 58.24M 7.43M 6.36M 5.95M 5.45M 10.23M 711M 10.36M 70.34M 27.43M 357M 27.89M 27.29M 1.18B | 35.55M 41.46M 5.29M 4.53M 4.24M 3.88M 7.28M 506M 7.38M 50.07M 19.53M 254M 19.86M 19.42M 841M |
| Net income | -508M -593M -75.59M -64.75M -60.59M -55.46M -104M -7.23B -105M -716M -279M -3.63B -284M -278M -12.02B | -223M -260M -33.12M -28.37M -26.54M -24.3M -45.6M -3.17B -46.2M -314M -122M -1.59B -124M -122M -5.26B |
| Net Debt | -2.29B -2.67B -341M -292M -273M -250M -470M -32.63B -476M -3.23B -1.26B -16.39B -1.28B -1.25B -54.21B | -1.93B -2.25B -287M -246M -230M -211M -395M -27.48B -401M -2.72B -1.06B -13.8B -1.08B -1.05B -45.66B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-21 | HK$1.015 | +3.57% | 2,820,500 |
| 26-08-20 | HK$0.9800 | +2.62% | 789,000 |
| 26-08-19 | HK$0.9550 | -3.54% | 382,500 |
| 26-08-18 | HK$0.9900 | -0.50% | 122,000 |
| 26-08-17 | HK$0.9950 | +1.02% | 435,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 2137 Stock
Select your edition
All financial news and data tailored to specific country editions
